Delaying Radioactive Iodine Ablation for up to One Year Does Not Increase Recurrence for Patients with Differentiated Thyroid Cancer

LivhitsMasha, J; YehMichael, W

doi:10.1089/ct.2016;28.346-348

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies showed that the duration between thyroidectomy and RAI ablation has no impact on the outcome [27], neither does the method of TSH level elevation (thyrotropin alpha (Thyrogen ® ) vs. withdrawal from thyroid hormone replacement) [7] nor the pre-ablation TSH level [28]. Thus, these three factors were precluded from the logistic regression analysis.…”

Section: Methodsmentioning

confidence: 99%

Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective

et al. 2018

View full text Add to dashboard Cite

Abstract. The lack of isolation ward throughout Japan has long been limiting the 131 I radioactive iodine (RAI) ablation for differentiated thyroid cancer (DTC) cases. The 30 mCi RAI ablation was only recently permitted for outpatient basis. However, no patient selection tool nor response predictor has been proposed. This study evaluated factors to find response predictor and determinant for the suitable patients. The retrospective study reviewed 47 eligible non-metastatic papillary DTC patients whose had first 30 mCi RAI ablation after total thyroidectomy. Age, gender, clinical stage, risk category, and preablation serum thyroglobulin (Tg) level were among covariates analyzed to determine the patient selection factors; while the thyroid bed uptake on initial whole body scan (WBS) was later also included in determining RAI ablation response. Thirteen (28%) patients had a low risk (T1-2) while 23 (49%) and 11 (23%) had an intermediate (T3) or high risk (T4), respectively. Twenty-five patients were responders, and 22 were non-responders. All factors were similar between responders and nonresponders except pre-ablation serum Tg level (p < 0.001). In multivariate analysis, pre-ablation serum Tg level was the only significant factor for both patient selection (odd ratio (OR) = 1.52, 95% confidence interval (CI) = 1.13-2.06) and response predictor (OR = 1.48; 95% CI = 1.12-1.95). With the cut-off of 5.4 ng/mL, pre-ablation serum Tg level predicts RAI ablation response with 92% specificity and 73% sensitivity. Pre-ablation serum Tg level may help patient selection and predict the response to outpatient 30 mCi RAI ablation among post total thyroidectomy non-metastatic DTC patients.

show abstract

Section: Methodsmentioning

confidence: 99%